相关实验视频

Updated: Mar 13, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

新辅助免疫治疗在不匹配修复缺陷/微卫星不稳定局部结肠癌患者中的挑战

M Karoui¹, A Mariani¹, J Taieb²

¹Department of Digestive and Oncological Surgery, Paris Cité University, Assistance Publique Hôpitaux de Paris, European Georges Pompidou University Hospital, Paris, France.

|March 11, 2026

概括

新辅助免疫疗法在不匹配修复缺陷 (dMMR) 结肠癌 (CC) 中显示出前景. 本综述提出了dMMR CC的管理算法,根据患者的病情和瘤特征指导免疫检查点抑制剂 (ICI) 的使用.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
胃肠道瘤学胃肠道瘤学

背景情况:

不匹配修复缺陷 (dMMR) 结肠癌 (CC) 已与新辅助免疫疗法显示出有效性.
在dMMR CC中新辅助免疫治疗的临床实践指南仍在发展.
免疫检查点抑制剂 (ICI) 是一种关键的治疗策略.

研究的目的:

对dMMR非转移性CC中新辅助剂/辅助剂ICI的关键临床试验进行审查.
为dMMR CC.开发一个实用的管理算法.
为了帮助临床决策,关于dMMR的免疫疗法.

主要方法:

对涉及dMMR非转移性CC的新辅助剂或辅助剂ICI的临床试验的系统审查.
分析试验结果以确定影响治疗决策的关键因素.
基于经过审查的证据,开发一种临床管理算法.

主要成果:

证据支持dMMRCC中新辅助免疫疗法的疗效和耐受性.
治疗决策的关键因素包括临床状态,瘤CT特征和治疗目标.
设计了一个算法来指导新辅助或辅助ICI的使用.

结论:

新辅助免疫疗法是dMMR CC.的可行选择.
拟议的算法为将ICI纳入临床实践提供了一个框架.
个性化治疗策略对于管理dMMRCC患者至关重要.

关键词:

在MSI/dMMR中使用.局部化结肠癌是局部化的结肠癌.新辅助免疫疗法新辅助免疫疗法没有转移的结肠癌.

更多相关视频

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

相关概念视频

Mismatch Repair

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...

Mismatch Repair

Mismatch Repair

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...